Number of clusters with identical <i>pncA</i> and others genes mutations.

<p>Number of clusters with identical <i>pncA</i> and others genes mutations.</p

Demography of RR-TB patients included in <i>pncA</i> analysis.

<p>Demography of RR-TB patients included in <i>pncA</i> analysis.</p

Number of sequences presenting a mutation in <i>pncA</i>.

<p>Number of sequences presenting a mutation in <i>pncA</i>.</p

Sampling fraction and additional resistance among RR-TB patients in the study.

<p>Sampling fraction and additional resistance among RR-TB patients in the study.</p

Flow chart of the samples included in our study.

<p>INH: isoniazid. RR: Rifampicin Resistance. MDR-TB: Multidrug resistant tuberculosis (<i>M</i>. <i>tuberculosis</i> resistant to both rifampicin and isoniazid). *Prospective study: An MDR-TB clinical study coordinated by the Union from 2012 to 2015 in nine African countries. **Retrospective study: consecutive RR-TB samples stored from 2014 to 2015 as part of routine drug resistance surveillance and/or for research purposes.</p

Number of samples with PZA resistance by category of patients.

<p>Number of samples with PZA resistance by category of patients.</p

Geographical origin and treatment history of the included patient samples (n = 605).

<p>Geographical origin and treatment history of the included patient samples (n = 605).</p